Dr Reddys Laboratories (RDY) EBITDA (2012 - 2026)

Dr Reddys Laboratories' EBITDA history runs 15 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• In Q1 2026, EBITDA fell 92.89% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $582.4 million (up 35.42% YoY), while the FY2026 annual figure was $539.0 million, down 35.99% from the prior year.
• EBITDA was $14.5 million for Q1 2026 at Dr Reddys Laboratories, down from $159.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $216.1 million in Q3 2023 to a low of -$24.0 million in Q4 2024.
• Historically, EBITDA has averaged $134.7 million across 5 years, with a median of $177.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA plunged 301.21% in 2024, then jumped 3138.38% in 2025.
• A 5-year view of EBITDA shows it stood at $150.8 million in 2022, then slumped by 92.1% to $11.9 million in 2023, then slumped by 301.21% to -$24.0 million in 2024, then soared by 766.98% to $159.9 million in 2025, then slumped by 90.93% to $14.5 million in 2026.
• The last three EBITDA figures came in at $14.5 million (Q1 2026), $159.9 million (Q4 2025), and $204.2 million (Q2 2025), per Business Quant data.